Master
Credit
Heading
Featured News: A novel strategy to suppress prostate cancer growth
Content
Dr. Yang’s team took a close look into what drives the growth of advanced tumors that have become resistant to standard castration therapy. Working with cells in the lab and animal models, they discovered an approach that suppresses the growth of therapy-resistant tumors. View press release and blog article.
Heading
Lab Related News
Content
- A potential strategy to control MAPK4-dependent cancer growth - Aug. 8, 2023
- A novel strategy to suppress triple negative breast cancer growth - Aug. 2, 2023
- From the Labs Top five most viewed posts of 2022 - Dec. 28, 2022
- MAPK4, novel therapeutic target for triple-negative breast cancer - Jan. 11, 2022
- New evidence supports a cancer-promoting role for enzyme MAPK6 (From the Labs) - Dec. 6, 2021
- Targeting MAPK4: potential therapy for prostate cancer - Feb. 23, 2021
- Baylor researchers receive nearly $2.7 million in CPRIT grants - Feb. 13, 2020
Heading
Recent Studies
Content
Our most recent studies featured by the Department of Defense research programs demonstrate the impact and importance of our studies:
- Department of Defense/Breast Cancer Research Program (2023 news)
"A potential strategy to control MAPK4-dependent cancer growth" - Department of Defense/Breast Cancer Research Program (2022 news)
“MAPK4 emerges as a novel therapeutic target for triple-negative breast cancer” - Department of Defense/Prostate Cancer Research Program (2021 news)
“MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT”
